High-Yield Pharmacogenomic Associations for the USMLE
Pharmacogenomics links inherited genetic variants to altered drug response — either dangerous toxicity, treatment failure, or the need for dose adjustment. For each association, anchor three facts: the gene/allele involved, the clinical consequence, and the required action (screen before use, genotype and dose-reduce, or switch drugs). These pairings are frequently tested because a single genetic mismatch can turn a routine prescription into a life-threatening event.
Abacavir & HLA-B*5701
Abacavir, used in HIV therapy, can trigger a severe hypersensitivity reaction in patients carrying the HLA-B*5701 allele. Because this reaction is potentially life-threatening, screening for HLA-B*5701 is MANDATORY before initiating abacavir. This is the classic example of pharmacogenomic testing that is required, not merely considered.
Carbamazepine & HLA-B*1502
Carbamazepine can precipitate Stevens-Johnson syndrome in patients carrying HLA-B*1502. This allele is enriched in Asian populations, so screening for HLA-B*1502 is recommended in Asian patients before starting carbamazepine. Recognize the pattern: a specific HLA allele predicting a severe cutaneous drug reaction.
6-Mercaptopurine / Azathioprine & TPMT
Thiopurines — 6-mercaptopurine (6-MP) and azathioprine — are inactivated by thiopurine methyltransferase (TPMT). Patients with TPMT deficiency cannot clear these drugs normally, leading to accumulation and severe myelosuppression. Genotype for TPMT before therapy and dose-reduce in deficient patients to avoid life-threatening bone marrow suppression.
Warfarin & CYP2C9 / VKORC1
Warfarin's response depends on two genes: CYP2C9, which metabolizes the drug, and VKORC1, which encodes warfarin's target (vitamin K epoxide reductase). Variants in either gene alter dose requirements, producing variable dosing needs across patients. Pharmacogenomic dosing algorithms can be used to improve time in the therapeutic range. Note separately that fluconazole inhibits CYP2C9 and can raise the INR by slowing warfarin metabolism.
Clopidogrel & CYP2C19
Clopidogrel is a prodrug that requires CYP2C19 for activation. Poor metabolizers (CYP2C19 PM) generate less active drug, producing a reduced antiplatelet effect and increased cardiovascular events. In these patients, consider switching to prasugrel or ticagrelor, which do not depend on CYP2C19 activation to the same degree.
Codeine & CYP2D6
Codeine is a prodrug converted to morphine by CYP2D6. Poor metabolizers get no analgesia because they cannot convert codeine to morphine. Ultra-rapid metabolizers produce excessive morphine, risking respiratory depression and death — especially dangerous in children, which underlies the FDA black box warning against codeine in pediatric tonsillectomy patients.
Prodrug vs. Direct-Acting: The Activation Concept
A recurring theme is whether the drug requires enzymatic activation. Clopidogrel and codeine are prodrugs — poor metabolizers experience treatment failure (no antiplatelet effect; no analgesia), while ultra-rapid metabolism of codeine causes toxicity. In contrast, TPMT deficiency impairs drug inactivation, so the parent thiopurine accumulates and causes toxicity. Deciding whether a variant causes failure or toxicity depends on whether the enzyme activates or inactivates the drug.
High-yield
- Abacavir + HLA-B*5701 = mandatory screening to prevent severe hypersensitivity reaction.
- Carbamazepine + HLA-B*1502 = Stevens-Johnson syndrome; screen in Asian populations.
- TPMT deficiency + 6-MP/azathioprine = severe myelosuppression; genotype and dose-reduce.
- Warfarin dosing is governed by CYP2C9 (metabolism) and VKORC1 (target).
- Clopidogrel CYP2C19 poor metabolizers = reduced antiplatelet effect; switch to prasugrel or ticagrelor.
- Codeine is activated by CYP2D6: poor metabolizers = no analgesia; ultra-rapid metabolizers = respiratory depression/death, especially in children.
- Two HLA-associated severe reactions to memorize: abacavir (HLA-B*5701) and carbamazepine (HLA-B*1502).
- Fluconazole inhibits CYP2C9 → decreased warfarin metabolism → elevated INR.
Pitfalls
- Confusing which HLA allele goes with which drug: HLA-B*5701 = abacavir, HLA-B*1502 = carbamazepine.
- Assuming poor metabolizers always get toxicity — for prodrugs like clopidogrel and codeine, poor metabolizers instead experience treatment failure.
- Forgetting that codeine ULTRA-rapid metabolizers, not poor metabolizers, are the ones at risk for fatal respiratory depression.
- Thinking VKORC1 metabolizes warfarin — VKORC1 is the drug's target; CYP2C9 is the metabolizing enzyme.
- Overlooking that carbamazepine screening is targeted to Asian populations rather than universal.
- Skipping TPMT genotyping before thiopurines and precipitating severe myelosuppression.
- Confusing enzyme inhibition (fluconazole raising INR) with inherited CYP2C9 variants — both alter warfarin effect but by different mechanisms.
Clinical pearls
- When a drug is a prodrug, a poor-metabolizer genotype means it won't work — not that it will build up.
- Two prescriptions that require a genetic gatekeeper: abacavir (screen HLA-B*5701) and thiopurines (genotype TPMT).
- If a clopidogrel-treated patient keeps having cardiovascular events, think CYP2C19 poor metabolizer and switch to prasugrel or ticagrelor.
- A new fluconazole prescription in a stable warfarin patient can spike the INR via CYP2C9 inhibition.
Frequently asked
Which pharmacogenomic test is absolutely mandatory before prescribing the drug?
HLA-B*5701 screening before abacavir. A positive result predicts a severe hypersensitivity reaction, so testing is required, not optional.
Why do clopidogrel poor metabolizers fail therapy, and what do you do?
Clopidogrel is a prodrug activated by CYP2C19. Poor metabolizers produce less active drug, giving a reduced antiplatelet effect and more cardiovascular events. Consider prasugrel or ticagrelor instead.
How do the two genes affect warfarin dosing?
CYP2C9 metabolizes warfarin, and VKORC1 encodes its target (vitamin K epoxide reductase). Variants in either alter dose requirements, so pharmacogenomic dosing algorithms can improve time in therapeutic range.
Why is codeine dangerous in children who are ultra-rapid metabolizers?
CYP2D6 converts codeine to morphine. Ultra-rapid metabolizers generate excessive morphine, causing respiratory depression and death — the basis for the FDA black box warning against codeine after pediatric tonsillectomy.
What happens if you give a thiopurine to a TPMT-deficient patient?
6-MP and azathioprine accumulate because TPMT normally inactivates them, leading to severe myelosuppression. Genotype for TPMT before therapy and dose-reduce in deficient patients.
Which HLA allele is linked to carbamazepine-induced Stevens-Johnson syndrome, and who should be screened?
HLA-B*1502. Screening is recommended in Asian populations because the allele is more common there.
A stable warfarin patient's INR jumps to 6.2 after starting a new drug — what mechanism should you suspect?
CYP2C9 inhibition. Fluconazole inhibits CYP2C9, slowing warfarin metabolism so it accumulates and raises the INR. CYP inducers like rifampin, carbamazepine, and phenobarbital would instead lower the INR.
How do you decide whether a metabolizer variant causes toxicity or treatment failure?
Determine whether the enzyme activates or inactivates the drug. For prodrugs (clopidogrel, codeine), poor metabolism causes failure; for drugs inactivated by an enzyme (thiopurines via TPMT), impaired metabolism causes accumulation and toxicity.
Turn this into reasoning you can use on exam day — practice High-Yield Pharmacogenomic Associations on branching cases where your decisions shape the patient.